| 1. |
Lantuejoul S, Fernandez-Cuesta L, Damiola F, et al. New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts. Transl Lung Cancer Res, 2020, 9(5): 2233-2244.
|
| 2. |
Yoshimura M, Seki K, Bychkov A, et al. Molecular pathology of pulmonary large cell neuroendocrine carcinoma: novel concepts and treatments. Front Oncol, 2021, 11: 671799.
|
| 3. |
呂田園, 張新峰, 王懷璋, 等. 晚期肺大細胞神經內分泌癌的臨床治療研究進展. 中國癌癥防治雜志, 2022, 14(5): 593-599.
|
| 4. |
Lowczak A, Kolasinska-Cwikla A, Osowiecka K, et al. Outcomes of patients with pulmonary large cell neuroendocrine carcinoma in I–IV stage. Medicina, 2021, 57(2): 118.
|
| 5. |
Xu FL, Chen K, Lu CL, et al. Large cell neuroendocrine carcinoma shares similarity with small cell carcinoma on the basis of clinical and pathological features. Transl Oncol, 2019, 12(4): 646-655.
|
| 6. |
Ferrara MG, Stefani A, Simbolo M, et al. Large cell neuro-endocrine carcinoma of the lung: current treatment options and potential future opportunities. Front Oncol, 2021, 11: 650293.
|
| 7. |
Le Treut J, Sault MC, Lena H, et al. Multicentre phase Ⅱ study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol, 2013, 24(6): 1548-1552.
|
| 8. |
Derks JL, van Suylen RJ, Thunnissen E, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J, 2017, 49(6): 1601838.
|
| 9. |
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med, 2015, 373(2): 123-135.
|
| 10. |
Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol, 2016, 17(7): 883-895.
|
| 11. |
Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol, 2016, 17(11): 1497-1508.
|
| 12. |
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med, 2018, 378(22): 2078-2092.
|
| 13. |
Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med, 2018, 379(21): 2040-2051.
|
| 14. |
Sherman S, Rotem O, Shochat T, et al. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer, 2020, 143: 40-46.
|
| 15. |
Agar C, Geier M, Léveiller G, et al. Brief report on the efficacy of nivolumab in patients with previously treated advanced large-cell neuroendocrine cancer of the lung. JTO Clin Res Rep, 2021, 2(4): 100129.
|
| 16. |
Dudnik E, Kareff S, Moskovitz M, et al. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. J Immunother Cancer, 2021, 9(2): e001999.
|
| 17. |
Putzu C, Canova S, Paliogiannis P, et al. Duration of immunotherapy in non-small cell lung cancer survivors: a lifelong commitment? Cancers, 2023, 15(3): 689.
|
| 18. |
Ben-Aharon O, Magnezi R, Leshno M, et al. Association of immunotherapy with durable survival as defined by value frameworks for cancer care. JAMA Oncol, 2018, 4(3): 326-332.
|
| 19. |
Harris SJ, Brown J, Lopez J, et al. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med, 2016, 13(2): 171-193.
|
| 20. |
Guo HF, Li WQ, Qian L, et al. Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer. Chin J Cancer Res, 2021, 33(2): 203-215.
|
| 21. |
Kadota N, Hatakeyama N, Hino H, et al. Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab. Cancer Rep (Hoboken), 2022, 5(8): e1589.
|
1/5
WeChat